Voltage-gated potassium channels as therapeutic targets

Heike Wulff; Neil A. Castle; Luis A. Pardo

doi:10.1038/nrd2983

Voltage-gated potassium channels as therapeutic targets

Heike Wulff, Neil A. Castle, Luis A. Pardo

Pharmacology

Research output: Contribution to journal › Article

425 Scopus citations

Abstract

The human genome encodes 40 voltage-gated K ⁺ channels (K _V), which are involved in diverse physiological processes ranging from repolarization of neuronal and cardiac action potentials, to regulating Ca 2⁺ signalling and cell volume, to driving cellular proliferation and migration. K_V channels offer tremendous opportunities for the development of new drugs to treat cancer, autoimmune diseases and metabolic, neurological and cardiovascular disorders. This Review discusses pharmacological strategies for targeting K_V channels with venom peptides, antibodies and small molecules, and highlights recent progress in the preclinical and clinical development of drugs targeting the K V 1 subfamily, the K_V 7 subfamily (also known as KCNQ), K_V 10.1 (also known as EAG1 and KCNH1) and K_V 11.1 (also known as HERG and KCNH2) channels.

Original language	English (US)
Pages (from-to)	982-1001
Number of pages	20
Journal	Nature Reviews Drug Discovery
Volume	8
Issue number	12
DOIs	https://doi.org/10.1038/nrd2983
State	Published - Dec 2009

Fingerprint

ASJC Scopus subject areas

Drug Discovery
Pharmacology
Medicine(all)

Cite this

Wulff, H., Castle, N. A., & Pardo, L. A. (2009). Voltage-gated potassium channels as therapeutic targets. Nature Reviews Drug Discovery, 8(12), 982-1001. https://doi.org/10.1038/nrd2983

@article{38a6034606154b6d8c49baed50a10dc5,

title = "Voltage-gated potassium channels as therapeutic targets",

abstract = "The human genome encodes 40 voltage-gated K + channels (K V), which are involved in diverse physiological processes ranging from repolarization of neuronal and cardiac action potentials, to regulating Ca 2+ signalling and cell volume, to driving cellular proliferation and migration. KV channels offer tremendous opportunities for the development of new drugs to treat cancer, autoimmune diseases and metabolic, neurological and cardiovascular disorders. This Review discusses pharmacological strategies for targeting KV channels with venom peptides, antibodies and small molecules, and highlights recent progress in the preclinical and clinical development of drugs targeting the K V 1 subfamily, the KV 7 subfamily (also known as KCNQ), KV 10.1 (also known as EAG1 and KCNH1) and KV 11.1 (also known as HERG and KCNH2) channels.",

author = "Heike Wulff and Castle, {Neil A.} and Pardo, {Luis A.}",

year = "2009",

month = dec

doi = "10.1038/nrd2983",

language = "English (US)",

volume = "8",

pages = "982--1001",

journal = "Nature Reviews Drug Discovery",

issn = "1474-1776",

publisher = "Nature Publishing Group",

number = "12",

}

TY - JOUR

T1 - Voltage-gated potassium channels as therapeutic targets

AU - Wulff, Heike

AU - Castle, Neil A.

AU - Pardo, Luis A.

PY - 2009/12

Y1 - 2009/12

N2 - The human genome encodes 40 voltage-gated K + channels (K V), which are involved in diverse physiological processes ranging from repolarization of neuronal and cardiac action potentials, to regulating Ca 2+ signalling and cell volume, to driving cellular proliferation and migration. KV channels offer tremendous opportunities for the development of new drugs to treat cancer, autoimmune diseases and metabolic, neurological and cardiovascular disorders. This Review discusses pharmacological strategies for targeting KV channels with venom peptides, antibodies and small molecules, and highlights recent progress in the preclinical and clinical development of drugs targeting the K V 1 subfamily, the KV 7 subfamily (also known as KCNQ), KV 10.1 (also known as EAG1 and KCNH1) and KV 11.1 (also known as HERG and KCNH2) channels.

AB - The human genome encodes 40 voltage-gated K + channels (K V), which are involved in diverse physiological processes ranging from repolarization of neuronal and cardiac action potentials, to regulating Ca 2+ signalling and cell volume, to driving cellular proliferation and migration. KV channels offer tremendous opportunities for the development of new drugs to treat cancer, autoimmune diseases and metabolic, neurological and cardiovascular disorders. This Review discusses pharmacological strategies for targeting KV channels with venom peptides, antibodies and small molecules, and highlights recent progress in the preclinical and clinical development of drugs targeting the K V 1 subfamily, the KV 7 subfamily (also known as KCNQ), KV 10.1 (also known as EAG1 and KCNH1) and KV 11.1 (also known as HERG and KCNH2) channels.

UR - http://www.scopus.com/inward/record.url?scp=73449119314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73449119314&partnerID=8YFLogxK

U2 - 10.1038/nrd2983

DO - 10.1038/nrd2983

M3 - Article

C2 - 19949402

AN - SCOPUS:73449119314

VL - 8

SP - 982

EP - 1001

JO - Nature Reviews Drug Discovery

JF - Nature Reviews Drug Discovery

SN - 1474-1776

IS - 12

ER -

Access to Document

10.1038/nrd2983